Literature DB >> 1609833

Neurology of the neuronal ceroid-lipofuscinoses: late infantile and juvenile types.

R M Boustany1.   

Abstract

My experience with more than 80 cases of the late infantile and juvenile forms of the neuronal ceroid-lipofuscinoses over the last 5 years has led to the following realizations. The 2 variants are neurologically distinct entities and probably are the result of different genetic defects. Treatment includes supportive measures and anticonvulsant medication. Therapy for behavioral and psychiatric disturbances in the juvenile type proves to be particularly challenging as neuroleptic medications tend to worsen parkinsonian like symptoms. Neuropathologic and neuroradiologic explanation of clinical symptomatology correlates best with neuronal loss and not neuronal storage. There is a paucity of neuropathologic documentation of these 2 types; additional reports are encouraged.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1609833     DOI: 10.1002/ajmg.1320420421

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  11 in total

1.  Juvenile neuronal ceroid lipofuscinosis.

Authors:  S Gulati; R Maheshwari; M Kabra; I C Verma; V Kalra
Journal:  Indian J Pediatr       Date:  2000-09       Impact factor: 1.967

2.  Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease).

Authors:  J M Kwon; H Adams; P G Rothberg; E F Augustine; F J Marshall; E A Deblieck; A Vierhile; C A Beck; N J Newhouse; J Cialone; E Levy; D Ramirez-Montealegre; L S Dure; K R Rose; J W Mink
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

Review 3.  Seizures, depression and dementia in teenagers with Batten disease.

Authors:  R M Boustany; P Filipek
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

4.  Nitric oxide signaling is disrupted in the yeast model for Batten disease.

Authors:  Nuno S Osório; Agostinho Carvalho; Agostinho J Almeida; Sérgio Padilla-Lopez; Cecília Leão; João Laranjinha; Paula Ludovico; David A Pearce; Fernando Rodrigues
Journal:  Mol Biol Cell       Date:  2007-05-02       Impact factor: 4.138

5.  Localization of juvenile, but not late-infantile, neuronal ceroid lipofuscinosis on chromosome 16.

Authors:  W Yan; R M Boustany; C Konradi; L Ozelius; T Lerner; J A Trofatter; C Julier; X O Breakefield; J F Gusella; J L Haines
Journal:  Am J Hum Genet       Date:  1993-01       Impact factor: 11.025

6.  Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy.

Authors:  L Vercammen; G M Buyse; J E F Proost; J L K Van Hove
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

7.  Neurodegeneration and Epilepsy in a Zebrafish Model of CLN3 Disease (Batten Disease).

Authors:  Kim Wager; Anselm A Zdebik; Sonia Fu; Jonathan D Cooper; Robert J Harvey; Claire Russell
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

8.  Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.

Authors:  Sara E Mole; Angela Schulz; Eben Badoe; Samuel F Berkovic; Emily C de Los Reyes; Simon Dulz; Paul Gissen; Norberto Guelbert; Charles M Lourenco; Heather L Mason; Jonathan W Mink; Noreen Murphy; Miriam Nickel; Joffre E Olaya; Maurizio Scarpa; Ingrid E Scheffer; Alessandro Simonati; Nicola Specchio; Ina Von Löbbecke; Raymond Y Wang; Ruth E Williams
Journal:  Orphanet J Rare Dis       Date:  2021-04-21       Impact factor: 4.123

9.  Designing a plan for drug discovery in rare pediatric neurodegenerative disease.

Authors:  Danielle Kerkovich; Amy Drew
Journal:  Cerebrum       Date:  2011-07-21

10.  Developmental Comparison of Ceramide in Wild-Type and Cln3 Δex7/8 Mouse Brains and Sera.

Authors:  Sally El-Sitt; Jihane Soueid; Jamal Al Ali; Joelle Makoukji; Nadine J Makhoul; Hayat Harati; Rose-Mary Boustany
Journal:  Front Neurol       Date:  2019-02-19       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.